Popular on s4story
- Postmortem Pathology Announces Private Autopsy Services for Families in Colorado
- DMV Native And Eight-Time Emmy Winner Justin W. Brown Directs A Moving Tribute To A Community's Legacy
- Bald Guy Greetings Launches Bold New Postcard Line Celebrating Over-the Top (and Often Delusional) Confidence
- Charming Ogawamachi Town, in Saitama Prefecture, Japan, Announces Festivals for 2025
- Gibson Gives Donates To Music City Chopin's Metro Nashville Piano Program
- Second Edition of Peernovation: Forged by CEOs. Perfected for Teams Now Available
- California Designer Margaret Rowe Launches Memoir
- ILTexas Begins Development of New High School In Colony Ridge Communities
- Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD: NRx: (Stock Symbol: NRXP)
- Jumpstart Summer Adventures at the Y
Similar on s4story
- K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
- Kemeny, Ramp & Renaud, LLC Welcomes Prominent Trusts and Estates Attorney Gary B. Cornick to Its Firm
- Electives Appoints DraftKings' CPO Linda Aiello to Board Amid Record Quarter
- Co-Creating the Future of ePaper: ZKONG and E Ink at Touch Taiwan 2025
- Webinar Announcement: Mexico's Evolving AML/CFT Environment: FATF Review and FTO Designations
- Emerging Managers Podcast Launches, Highlighting New Players in Venture Capital Outperforming the Status Quo
- Home Run Pest & Termite Control Launches Monthly Mosquito Service to Help Wylie, Plano, and Rockwall Homeowners Reclaim Their Backyards
- T&S and US Conec Ink Global Licensing Deal on MDC Technology to Advance High-Density Optical Interconnects
- Coming Up on "Financial Freedom with Tom Hegna" Retirement Authority Daniel Rondberg from Nation's First Financial
- The Ten News Wins 2025 Ambie Award for Best News Podcast
Phantom Neuro Secures $19M Series A Funding Led by Ottobock to Advance Neural Interface Technology for Prosthetics and Robotics
S For Story/10656393
AUSTIN, Texas, April 15, 2025 ~ In a major development for the field of neurotechnology, Phantom Neuro has announced an oversubscribed $19 million Series A funding round led by Ottobock, a global leader in prosthetics, orthotics, and exoskeleton technology. The round also includes participation from existing investors such as Breakout Ventures, Draper Associates, LionBird Ventures, Time BioVentures, and Risk and Return, as well as new investors Actual VC, METIS Innovative, e1 Ventures, Jumpspace, MainSheet Ventures, and Brown Advisory.
This latest investment brings Phantom Neuro's total funding to $28 million and marks a significant milestone in the company's mission to bring its Phantom X robotic control platform to patients. The funds will be used to support preclinical testing, complete first-in-human trials, submit regulatory applications, and expand research and development for broader control applications beyond prosthetic limbs.
More on S For Story
Dr. Connor Glass, Founder and CEO of Phantom Neuro expressed his excitement about Ottobock's involvement in the funding round. He stated that Ottobock's support highlights the growing convergence of neurotechnology with prosthetics and robotics. He also added that Ottobock has been at the forefront of restoring mobility for millions of people for decades and partnering with them will accelerate Phantom X's path to market.
As part of the investment deal, Ottobock will join Phantom Neuro's Board of Directors. This move brings valuable expertise in global prosthetics and exoskeleton markets to support Phantom's commercialization efforts.
Ottobock CEO Oliver Jakobi shared his enthusiasm about the partnership with Phantom Neuro. He stated that their investment reflects their ambition as a MedTech champion to lead the prosthetics market by providing patients with access to the most effective solutions possible. He also expressed his excitement about working with Phantom Neuro to expand access to their groundbreaking technology.
More on S For Story
This funding comes on the heels of two significant designations received by Phantom X from the U.S. Food and Drug Administration (FDA) - Breakthrough Device Designation and TAP (Targeted Acceleration Pathway) Designation. These designations validate the platform's potential to improve patient outcomes by providing lifelike control of prosthetic limbs and assistive devices, and also help expedite regulatory approvals.
In addition to these achievements, Phantom Neuro's ASCENT study demonstrated that Phantom X achieved an impressive 94% accuracy in decoding real-time gestures across 11 essential hand and wrist movements. This further supports the platform's potential to restore function and independence for individuals with mobility impairments.
With this latest round of funding and support from Ottobock, Phantom Neuro is well-positioned to continue its groundbreaking work in advancing human-machine interfaces and revolutionizing the field of neurotechnology.
This latest investment brings Phantom Neuro's total funding to $28 million and marks a significant milestone in the company's mission to bring its Phantom X robotic control platform to patients. The funds will be used to support preclinical testing, complete first-in-human trials, submit regulatory applications, and expand research and development for broader control applications beyond prosthetic limbs.
More on S For Story
- Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
- Former Orange County Commissioner Homer Hartage Announces Heartwarming New Children's Picture Book
- Baltimore Author Crafts Space Opera Where Human Questions Outshine Galactic Scale
- Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
- OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
Dr. Connor Glass, Founder and CEO of Phantom Neuro expressed his excitement about Ottobock's involvement in the funding round. He stated that Ottobock's support highlights the growing convergence of neurotechnology with prosthetics and robotics. He also added that Ottobock has been at the forefront of restoring mobility for millions of people for decades and partnering with them will accelerate Phantom X's path to market.
As part of the investment deal, Ottobock will join Phantom Neuro's Board of Directors. This move brings valuable expertise in global prosthetics and exoskeleton markets to support Phantom's commercialization efforts.
Ottobock CEO Oliver Jakobi shared his enthusiasm about the partnership with Phantom Neuro. He stated that their investment reflects their ambition as a MedTech champion to lead the prosthetics market by providing patients with access to the most effective solutions possible. He also expressed his excitement about working with Phantom Neuro to expand access to their groundbreaking technology.
More on S For Story
- Two exciting new fantasy & adventure books are published
- MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
- "The Eyes Have It" a Short Story by Philip K. Dick Now Available on Audiobook
- New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY
- Fairfield Inn by Marriott Scottsdale Old Town Opens
This funding comes on the heels of two significant designations received by Phantom X from the U.S. Food and Drug Administration (FDA) - Breakthrough Device Designation and TAP (Targeted Acceleration Pathway) Designation. These designations validate the platform's potential to improve patient outcomes by providing lifelike control of prosthetic limbs and assistive devices, and also help expedite regulatory approvals.
In addition to these achievements, Phantom Neuro's ASCENT study demonstrated that Phantom X achieved an impressive 94% accuracy in decoding real-time gestures across 11 essential hand and wrist movements. This further supports the platform's potential to restore function and independence for individuals with mobility impairments.
With this latest round of funding and support from Ottobock, Phantom Neuro is well-positioned to continue its groundbreaking work in advancing human-machine interfaces and revolutionizing the field of neurotechnology.
0 Comments
Latest on S For Story
- CCHR Florida to Host a Veteran Advocates Networking Event
- Students Celebrate Earth Month and Learn About the Lifecycle of Trees
- Electives Appoints DraftKings' CPO Linda Aiello to Board Amid Record Quarter
- Blue Ocean Business School's Deputy Dean Delivers Keynote Address at India Blockchain Summit
- AdvisorVault's Consolidated 17a-4 D3P Service® Full Feature Set Available
- Most Common Car Accidents In America
- Meet Local Author Turning Grief Into Page-Turning Love Story This Saturday for Independent Bookstor
- Lark Compton's book of Poetry and Art, Diving Into the Beloved
- A Great Speech Can Change The World (and Your Business)
- Owl & Jest Announces the 2025 Release of Moving to Portugal Made Simple
- New from Down & Out Books: POLITICAL ALLIANCES by G. Miki Hayden
- Co-Creating the Future of ePaper: ZKONG and E Ink at Touch Taiwan 2025
- New York Times Exposé Vindicates CCHR: ADHD Isn't Biological, Says Watchdog
- Author Says the Turmoil of World War II Still Plagues America
- HISTORIC FIRST The First Belief System In Human History To Formally Enshrine The Innate Divinity Of The Infant As Civilization's Central Moral Axis
- Stuck in Place? Why Homeowners Are Building Up Instead of Moving Out
- Crafting the Sound of VS Pop™: The Vision of CR Srikanth
- Boston Industrial Solutions, Inc., introduces Rubber and Foam Printing Ink
- FeelWise to Exhibit at ATD 2025 International Conference & EXPO in Washington, DC
- Webinar Announcement: Mexico's Evolving AML/CFT Environment: FATF Review and FTO Designations